PDF
Published
2024-12-12
Issue
Section
Pharmacy Practice & Practice-Based Research
Categories
License
Copyright (c) 2024 Annika Skogg, Alicia Zagel, R. May O'Donnell, Ann Philbrick, Mary Nelson, Allyson Schlichte, Kassie Klasen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of content published in INNOVATIONS in pharmacy belongs to the author(s).
Implementation of a Targeted Technologic Screening Tool to Increase Pneumococcal Vaccine Uptake in Health-System Retail Pharmacies: A Quality Improvement Initiative
Annika Skogg
Fairview Pharmacy Services
Alicia Zagel
Fairview Pharmacy Services
https://orcid.org/0000-0002-9168-1862
R. May O'Donnell
Fairview Pharmacy Services
https://orcid.org/0009-0008-2976-1993
Ann Philbrick
M Health Fairview Bethesda Clinic
https://orcid.org/0000-0003-0322-9532
Mary Nelson
Fairview Pharmacy Services
https://orcid.org/0009-0001-1052-3724
Allyson Schlichte
Fairview Pharmacy Services
Kassie Klasen
Fairview Pharmacy Services
https://orcid.org/0009-0003-7117-4614
DOI: https://doi.org/10.24926/iip.v15i4.6345
Keywords: pneumococcal vaccines, technology, pharmacy-based immunizations
Abstract
Background/Purpose: Pneumococcal vaccine rates among eligible adults are lower than desired. Recently, pneumococcal vaccination guidelines for adults were updated to include new pneumococcal conjugate vaccines (PCV20), taking into consideration age, underlying risk factors, and previous vaccine status. To respond to PCV undervaccination and help clarify the new guidelines, this project sought to develop a targeted pneumococcal vaccine screening tool and pop-up alert within retail pharmacies across a large health system with the goal of increasing rates of PCV20 vaccination.
Methods: A PDSA cycle was employed to activate alerts within 24 retail pharmacies for patients indicated to be eligible for PCV20 vaccination. PCV20 vaccine-naïve adult patients who met eligibility requirements and were due for medication refill were identified through the electronic health record and uploaded to pharmacy software. Pharmacists screened patients for eligibility and inquired about willingness to receive PCV20 vaccine during the upcoming pharmacy visit. Vaccine rates and sociodemographic characteristics were compared before and after the PDSA cycle began, and reasons for patient decline were assessed.
Results: Between December 2023 and April 2024, 1821 patients were screened for PCV20 vaccines, with 1369 (75%) patients eligible. 130 patients (9%) ultimately received PCV20 through the alert process, yet an additional 285 PCV20 vaccines were administered to additional patients, representing a 140% increase in PCV20 vaccination rates compared to the same period of the previous year. The most common reason for declining vaccination was no interest in vaccines (n=231, 51%).
Conclusions: This PDSA cycle demonstrated a vast increase in PCV20 vaccination rates in retail pharmacies across a large health system, indicating the potential utility of integrated technologic screening tools and alerts to increase administration of other routine immunizations.
